Comparative Pharmacology
Head-to-head clinical analysis: BROMOCRIPTINE MESYLATE versus NEUPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMOCRIPTINE MESYLATE versus NEUPRO.
BROMOCRIPTINE MESYLATE vs NEUPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromocriptine mesylate is a dopamine D2 receptor agonist that also exhibits partial agonist activity at D1 receptors. By stimulating dopamine receptors in the tuberoinfundibular pathway, it inhibits prolactin secretion from the anterior pituitary. It also activates postsynaptic dopamine receptors in the striatum, improving motor function in Parkinson disease. Additionally, it has been shown to improve glycemic control in type 2 diabetes by modulating central dopaminergic tone and reducing hepatic glucose production.
Rotigotine is a non-ergoline dopamine agonist with high affinity for dopamine D1, D2, D3, D4, and D5 receptors; also binds to serotonin 5-HT1A and alpha2-adrenergic receptors.
Oral: 1.25-2.5 mg twice daily, increased gradually as tolerated. Maximum 100 mg/day. Also used intravaginally for hyperprolactinemia (2.5 mg once daily).
Apply transdermally once daily; initial dose 2 mg/24h, titrated weekly by 2 mg/24h up to 6 mg/24h, maximum 8 mg/24h.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged to 12-14 hours in patients with hepatic impairment or in the elderly.
Single dose: 5-7 hours (transdermal); steady state: 7-10 hours; effective half-life for dosing is 8 hours due to reservoir in skin
Primarily hepatic metabolism with 85-90% fecal excretion via bile; <5% renal excretion as unchanged drug and metabolites.
Renal: 45% (metabolites), Fecal: 40% (metabolites), Biliary: 15%
Category A/B
Category C
Dopamine Agonist
Dopamine Agonist